Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma

Inclusion Criteria: * Patients must have histologically confirmed mantle cell lymphoma (MCL) * Please note: Measurable disease is not required, but will be followed if it exists * Patients must have received 4 or more cycles of one of the following prior systemic induction chemotherapy regimens: * Rituximab, cyclophosphamide, doxorubicin hydrochloride (hydroxydaunomycin), vincristine sulfate (Oncovin), prednisone (R-CHOP) (with or without alternating rituximab, dexamethasone, cytarabine \[ara-c\], cisplatin \[platinum\] \[R-DHAP\]) with or without autologous (auto) stem cell transplant (SCT) * Hyper-cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride (adriamycin), dexamethasone (CVAD) with or without auto SCT * Bendamustine + rituximab with or without auto SCT * Please note: * Patients who received combinations of the above regimens are not eligible for enrollment * At the time of registration, patients must be at least 14 days out from last dose of cytotoxic chemotherapy, but no more than 90 days; if a patient underwent auto SCT, he/she must demonstrate engraftment (per treating investigator's discretion) and must meet all other hematological requirements as outlined below * Patients must have achieved a response to induction chemotherapy (either CR or PR by Cheson 2007 criteria) and be without known progression * Patients may have received prior radiotherapy * Patients must exhibit an Eastern Cooperative Oncology Group (ECOG) perfor…